Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600
Debt
Debt-to-Equity Ratio3.00
Current Ratio1.62
Quick Ratio0.97
Price-To-Earnings
Trailing P/E Ratio-11.11
Forward P/E Ratio-13.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$383.41 million
Price / Sales0.89
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book7.14
Profitability
EPS (Most Recent Fiscal Year)($0.36)
Net Income$-29,570,000.00
Net Margins-7.00%
Return on Equity-52.91%
Return on Assets-6.25%
Miscellaneous
Employees944
Outstanding Shares85,640,000
Accuray (NASDAQ:ARAY) Frequently Asked Questions
What is Accuray's stock symbol?
Accuray trades on the NASDAQ under the ticker symbol "ARAY."
How were Accuray's earnings last quarter?
Accuray Incorporated (NASDAQ:ARAY) released its quarterly earnings results on Monday, April, 30th. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The medical equipment provider earned $99.83 million during the quarter, compared to analysts' expectations of $98.18 million. Accuray had a negative net margin of 7.00% and a negative return on equity of 52.91%. View Accuray's Earnings History.
When is Accuray's next earnings date?
What price target have analysts set for ARAY?
6 analysts have issued twelve-month price objectives for Accuray's stock. Their predictions range from $6.00 to $10.00. On average, they expect Accuray's stock price to reach $7.40 in the next year. View Analyst Ratings for Accuray.
Who are some of Accuray's key competitors?
Some companies that are related to Accuray include Orthofix International (OFIX), Atrion (ATRI), Intersect ENT (XENT), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Tandem Diabetes Care (TNDM), Cryolife (CRY), AtriCure (ATRC), K2M Group (KTWO), Tactile Systems Technology (TCMD), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX), LeMaitre Vascular (LMAT) and MiMedx Group (MDXG).
Who are Accuray's key executives?
Accuray's management team includes the folowing people:
- Mr. Joshua H. Levine, Pres, Chief Exec. Officer & Director (Age 60)
- Mr. Kevin Waters, Sr. VP & CFO (Age 41)
- Mr. Andrew Kirkpatrick, Sr. VP of Global Operations (Age 55)
- Ms. Alaleh Nouri, Sr. VP, Gen. Counsel & Corp. Sec. (Age 39)
- Mr. Lionel Hadjadjeba, Sr. VP & Chief Commercial Officer (Age 59)
Has Accuray been receiving favorable news coverage?
Press coverage about ARAY stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Accuray earned a daily sentiment score of 0.01 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 45.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Accuray's major shareholders?
Accuray's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.45%), Neuberger Berman Group LLC (5.33%), Russell Investments Group Ltd. (5.18%), Heartland Advisors Inc. (3.71%), Boston Partners (3.07%) and Dimensional Fund Advisors LP (2.19%). Company insiders that own Accuray stock include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Institutional Ownership Trends for Accuray.
Which institutional investors are selling Accuray stock?
ARAY stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Millennium Management LLC, Spark Investment Management LLC, Heartland Advisors Inc., Granite Investment Partners LLC, Neuberger Berman Group LLC, UBS Group AG and Lapides Asset Management LLC. Company insiders that have sold Accuray company stock in the last year include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Insider Buying and Selling for Accuray.
Which institutional investors are buying Accuray stock?
ARAY stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Legal & General Group Plc, BlackRock Inc., Global X Management Co. LLC, Dimensional Fund Advisors LP, Boston Partners, Mackay Shields LLC and Algert Global LLC. View Insider Buying and Selling for Accuray.
How do I buy shares of Accuray?
Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accuray's stock price today?
One share of ARAY stock can currently be purchased for approximately $4.00.
How big of a company is Accuray?
Accuray has a market capitalization of $336.13 million and generates $383.41 million in revenue each year. The medical equipment provider earns $-29,570,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Accuray employs 944 workers across the globe.
How can I contact Accuray?
Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]
MarketBeat Community Rating for Accuray (ARAY)
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
